• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Minerals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Optinose Announces Launch of Public Offering of Common Stock

    Gabrielle Lakusta
    Jun. 05, 2018 08:52AM PST
    Pharmaceutical Investing

    OptiNose (NASDAQ:OPTN), announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) and commenced a proposed underwritten public offering of 4,500,000 shares of its common stock. The offering is expected to consist of 2,250,000 shares to be offered by Optinose and 2,250,000 shares to be offered …

    OptiNose (NASDAQ:OPTN), announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) and commenced a proposed underwritten public offering of 4,500,000 shares of its common stock. The offering is expected to consist of 2,250,000 shares to be offered by Optinose and 2,250,000 shares to be offered by certain selling stockholders.

    As quoted in the press release:

    In addition, Optinose and the selling stockholders are expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional 675,000 shares at the public offering price, less the underwriting discount. Optinose will not receive any proceeds from the sale of shares by the selling stockholders. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.

    Jefferies and Piper Jaffray will act as the lead joint book-running managers for the offering. BMO Capital Markets and RBC Capital Markets will also act as joint book-running managers for the offering and Cantor will act as sole lead manager.

    Click here to read the full press release.

    pharmaceutical investing
    The Conversation (0)

    Go Deeper

    AI Powered

    Oncobiologics Receives Positive Nasdaq Listing Determination

    Microbot Medical Announces $5.9 Million Registered Direct Offering Priced At-the-Market

    Latest News

    Outlook Reports world

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Cardiol Therapeutics

    CRDL:CA

    Invion Limited

    IVX:AU

    Principal Technologies

    PTEC:CC
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES